Disease burden of fractures among patients with osteoporosis in Japan: health-related quality of life, work productivity and activity impairment, healthcare resource utilization, and economic costs.


Journal

Journal of bone and mineral metabolism
ISSN: 1435-5604
Titre abrégé: J Bone Miner Metab
Pays: Japan
ID NLM: 9436705

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 15 11 2017
accepted: 14 02 2018
pubmed: 10 3 2018
medline: 7 5 2019
entrez: 10 3 2018
Statut: ppublish

Résumé

Osteoporosis remains undertreated in Japan, and bone fractures are the most frequent complications imposing heavy burden on individuals and the community. This paper investigates the clinical and economic burden of fractures among osteoporosis patients in Japan. The Japan National Health and Wellness Survey 2012-2014 database was used for analysis. Respondents aged ≥ 50 years and indicated a physician diagnosis of osteoporosis (N = 1107) were categorized into three subgroups: no prior fracture (N = 693), single fracture (N = 242), and multiple (≥ 2) fractures (N = 172). Health-related quality of life (HRQoL), work productivity and activity impairment, healthcare resource utilization and associated direct and indirect costs were compared across three fracture subgroups adjusting for respondents' sociodemographic and clinical characteristics using generalized linear regression models. The estimated fracture prevalence among respondents with osteoporosis who were ≥ 50 years was 37.4%, of whom 41.5% had multiple fractures. Relative to osteoporosis respondents with no fracture and with single fracture, those with multiple fractures reported significant higher disability in HRQoL, more healthcare resource utilization, and were associated with higher direct costs. Improved treatment of fractures among osteoporosis patients is necessary and may help reduce the clinical and economic burden in this osteoporosis population.

Identifiants

pubmed: 29520508
doi: 10.1007/s00774-018-0916-1
pii: 10.1007/s00774-018-0916-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

307-318

Références

Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Osteoporos Int. 2000;11(7):556-61
pubmed: 11069188
J Health Econ. 2002 Mar;21(2):271-92
pubmed: 11939242
Osteoporos Int. 2002;13(4):323-30
pubmed: 12035765
Lancet. 2002 May 18;359(9319):1761-7
pubmed: 12049882
Bone. 2002 Jul;31(1):32-6
pubmed: 12110409
Osteoporos Int. 2004 Jan;15(1):38-42
pubmed: 14593451
Pharmacoeconomics. 2004;22(3):165-84
pubmed: 14871164
Osteoporos Int. 2004 Oct;15(10):834-41
pubmed: 15045468
Osteoporos Int. 2005 Jan;16(1):1-5
pubmed: 15565349
Osteoporos Int. 2005 May;16(5):447-55
pubmed: 15609073
Best Pract Res Clin Rheumatol. 2006 Aug;20(4):695-706
pubmed: 16979533
Panminerva Med. 2007 Mar;49(1):21-7
pubmed: 17468730
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
J Bone Miner Res. 2010 Feb;25(2):369-78
pubmed: 19594298
Curr Rheumatol Rep. 2010 Jun;12(3):186-91
pubmed: 20425518
Rev Saude Publica. 2010 Jun;44(3):479-85
pubmed: 20549019
Appl Health Econ Health Policy. 2011 Mar 1;9(2):111-23
pubmed: 21271750
Calcif Tissue Int. 2012 Jan;90(1):14-21
pubmed: 22076525
Curr Osteoporos Rep. 2012 Dec;10(4):245-7
pubmed: 22898971
Osteoporos Int. 2013 Jan;24(1):23-57
pubmed: 23079689
Osteoporos Int. 2013 Mar;24(3):811-23
pubmed: 23306819
Yonago Acta Med. 2012 Jun;55(2):21-8
pubmed: 24031136
Arch Osteoporos. 2014;9:187
pubmed: 24970672
Arch Osteoporos. 2014;9:199
pubmed: 25391755
J Osteoporos. 2014;2014:909153
pubmed: 25587485
Nat Sci Sleep. 2015 Jan 05;7:1-11
pubmed: 25610008
J Pain Res. 2015 Feb 25;8:119-30
pubmed: 25750546
Bone Res. 2014 Apr 29;2:14001
pubmed: 26273515
J Osteoporos. 2015;2015:627631
pubmed: 26783494
J Med Econ. 2016 Jul;19(7):702-9
pubmed: 26929988
J Clin Med Res. 2017 May;9(5):382-387
pubmed: 28392857
Clinicoecon Outcomes Res. 2017 Jun 23;9:361-371
pubmed: 28694702
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Arthritis Rheum. 1993 Jun;36(6):750-6
pubmed: 8507215

Auteurs

Saeko Fujiwara (S)

Hiroshima Atomic Bomb Casualty Council, Hiroshima, Japan.

Xiahong Zhao (X)

Kantar Health, Singapore, Singapore. zxiahong@gmail.com.

Cheryl Teoh (C)

Kantar Health, Singapore, Singapore.

Dena H Jaffe (DH)

Kantar Health, Tel Aviv, Israel.

Yurie Taguchi (Y)

Amgen Astellas BioPharma K.K., Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH